Small UK biotech Synairgen plc has announced some big news on its inhaled interferon beta candidate, SNG001, which significantly reduced the risk of severe disease in hospitalized patients with COVID-19, sending the firm's shares through the roof.
Southampton-based Synairgen has unveiled preliminary data from a study that recruited 101 patients from nine specialist hospital sites in the...






